The Food and Drug Administration (FDA) has removed Dr. Tracy Beth Hoeg from her role as acting director of the agency's drug center, replacing her with Dr. Mike Davis. Hoeg, who had been in the position since December, announced on social media that she was 'fired' from the agency. The move is part of a broader leadership shake-up at the FDA, which has seen multiple high-profile departures in recent weeks.
Key Developments
Hoeg's Removal: Hoeg, who had no prior government or management experience, was promoted rapidly by former FDA Commissioner Marty Makary. Her departure follows Makary's resignation earlier this week and the stepping down of Dr. Vinay Prasad, the agency's vaccine and biotech chief, last month. Hoeg's replacement, Dr. Mike Davis, had been serving as deputy director.
Leadership Changes: The FDA also announced that Karim Mikhail, a longtime pharmaceutical executive, will take over as acting director of the vaccines center. Mikhail was hired by Makary last spring. The agency has faced criticism from President Donald Trump's political allies, including anti-abortion groups and vaping lobbyists, who have expressed frustration with the FDA's direction.
Context and Reactions
Background on Hoeg's Role: Hoeg's rapid rise within the FDA was engineered by Makary, who promoted her from special assistant to leading the agency's largest center, responsible for regulating most U.S. prescription and over-the-counter drugs. Typically, FDA center directors are career agency scientists with decades of experience.
Criticism and Support: Hoeg's departure comes amid intense criticism from drugmakers, patients, and investors. The FDA has been under scrutiny for its handling of COVID-19 vaccines, antidepressants, and other widely used therapies. Hoeg's alignment with Makary and Health Secretary Robert F. Kennedy Jr. has also drawn attention.
Broader Implications: The leadership changes at the FDA raise questions about the agency's future direction and its ability to regulate critical health products. The revolving door of leadership could impact the agency's operations and public trust in its decisions.